Sanofi

2 Maj 2011 14:09

Ny studie visar på en signifikant minskning av antalet skov per år och uppbromsning av sjukdomsprogressen hos MS-patientersom byter till Copaxone® (glatirameracetat)

Data som presenterades visar också att 70 procent av patienterna fick en förbättrad eller stabiliserad kognition efter behandling med Copaxone®. Data presenterade vid det 63:e årsmötet för American Academy of Neurology (AAN) i Honolulu på Hawaii.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) presenterade under AAN preliminära data från två studier, Coptimize och QualiCop.
Den globala C

12 April 2011 11:29

Lixisenatide Significantly Reduces HbA1c Without Increasing Hypoglycemia in Patients Uncontrolled on Sulfonylureas

Sanofi-aventis announced today that lixisenatide, a once-daily GLP-1 receptor agonist under development for people with Type 2 diabetes, achieved its primary efficacy objective of significant HbA1c reduction and improved glycemic control from baseline versus placebo. The top-line results also showed that people treated with lixisenatide had a significant decrease in body weight.

4 April 2011 11:27

Jevtana® har godkänts som andrahandsbehandling av framskriden prostatacancer – Första preparatet som signifikant förlänger total överlevnad hos mHRPC-patienter

EU-kommissionen har nu godkänt Jevtana (cabazitaxel), i kombination med prednison eller prednisolon, för behandling av patienter med metastatisk hormonrefraktär prostatacancer (mHRPC) som tidigare fått docetaxel-baserad behandling. Resultat från TROPIC-studien visade att Jevtana ger mer än hälften av patienterna åtminstone ett år till att leva.

21 Mars 2011 09:24

Sanofi-aventis and its employees Donate to Tohoku Pacific Earthquake Relief Fund

Sanofi-aventis will donate 1 million Euros to support the aid relief efforts of the Japan Red Cross through the Sanofi Espoir Foundation for the Tohoku Pacific Earthquake and Tsunami that struck the area on March 11, 2011. Additionally, an appeal for generosity has been launched across all countries and affiliates worldwide, inviting employees who wish to join in this solidarity effort.

9 Mars 2011 14:02

Sanofi-aventis signs New Agreement with the World Health Organization (WHO) to fight Neglected Tropical Diseases

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today it had signed a new agreement to donate $25 million, extending its decade-long partnership with the World Health Organization (WHO) for another five years to control neglected tropical diseases, including the potentially fatal Human African Trypanosomiasis, also known as sleeping sickness.

26 Januari 2011 16:07

Nytt cancerläkemedel mot prostatacancer rekommenderas för godkännande inom EU

CHMP inom EMA har gett ett positivt utlåtande (”positive opinion”) där de rekommenderar att JEVTANA® (cabazitaxel) ska godkännas för försäljning inom EU. Rekommendationen gäller JEVTANA® i kombination med prednison eller prednisolon, och avser behandling av patienter med metastatisk hormonrefraktär prostatacancer (mHRPC) som tidigare fått docetaxel-baserad behandling.

21 December 2010 16:03

Sanofi-aventis Acquires from Ascendis Pharma Worldwide Rights on Drug-Delivery Technology in Diabetes and Related Disorders

Sanofi-aventis and Ascendis Pharma announced today a global licensing and patent transfer agreement on Ascendis’ proprietary TransCon Linker and Hydrogel carrier technology, which allows for a drug compound to be released in the body in a precise, time-controlled fashion, creating a long-acting effect.

14 December 2010 15:06

”Svensk cancervård är inte rättvis”

Stora regionala skillnader, brist på urologer och kunskapsluckor skapar en orättvis cancervård i Sverige. Det slog en enig debatt fast vid ett kvällsseminarium i Stockholm. Samtidigt visade panelen att det finns en stark vilja att förändra vården och skapa bättre förutsättningar för alla att få tillgång till god och kvalitativ vård.

14 December 2010 14:57

Sanofi-aventis appoints Dr. Elias Zerhouni, President, Global Research & Development

Sanofi-aventis is pleased to announce the appointment of Dr. Elias Zerhouni as President, Global Research & Development, covering Medicines and Vaccines, effective January 1, 2011. Dr. Zerhouni will report directly to Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis, and join the Executive Committee and the Management Committee.

28 Oktober 2010 16:55

Resilient sales and business EPS in Q3 2010

Commenting on the Group’s performance in Q3 2010, sanofi-aventis Chief Executive Officer, Christopher A. Viehbacher said, “This third quarter was marked by the success of the Jevtana® launch in the U.S., by positive Phase III data for lixisenatide and teriflunomide but also by the entry of a generic of Lovenox® in the U.S. Our Q3 results were also enhanced by favourable currency tailwind. Tight co

18 Oktober 2010 09:19

Sanofi-aventis Establishes Research Collaboration with Harvard University

Sanofi-aventis announced today a research collaboration with Harvard University. The goal of the collaboration is to advance knowledge in the area of human health through basic and applied research and to promote scientific exchange between Harvard University and sanofi-aventis. The focus is translational biomedical research in multiple therapeutic areas such as cancer, diabetes and inflammation.

15 Oktober 2010 09:28

Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients

Sanofi-aventis announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both doses of teriflunomide (7 and 14mg) significantly reduced annualized relapse rate (primary study endpoint) by 31% vs. placebo (p≤0.0005).

Nyhetsarkiv